Article Details

Long-Term Follow-Up Continues to Show Acalabrutinib-Based Regimens Superior to ...

Retrieved on: 2022-06-04 17:18:04

Tags for this article:

Click the tags to see associated articles and topics

Long-Term Follow-Up Continues to Show Acalabrutinib-Based Regimens Superior to .... View article details on hiswai:

Excerpt

Patients with treatment-naïve chronic lymphocytic leukemia (CLL) who received treatment with acalabrutinib (Calquence) either as a single-agent or in ...

Article found on: www.cancernetwork.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up